| abstract |
While the extracellular accumulation of amyloid-ß in the brain parenchyma is a pathological hallmark of Alzheimer's disease, its role as a cause or a consequence of AD is still debated. As described herein, intracellular Aß1-42 is shown to be selectively toxic to neurons. The present invention provides methods of screening for compounds for the prevention and treatment of A amyloid associated diseases such as Alzheimer's disease, Down's Syndrome, cerebral amyloid angiopathy, and inclusion body myositis. |